(S012) Trends in the Selection of Definitive Treatment for Newly Diagnosed Prostate Cancer in Men < 60 Years Old

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

In this young patient population, no definitive treatment was selected in 22.5% of men with LR disease. For those with HR disease, 25.5% did not undergo active treatment, indicating that these men appear to be receiving less aggressive therapy than recommended by NCCN guidelines. In addition, African-American race is also associated with a decreased likelihood for receipt of definitive therapy.

Joseph Safdieh, MD, J. Rineer, MD, M. Shao, MD, E. Navo, MD, D. Schreiber, MD; SUNY Downstate Medical Center; University of Florida Health Cancer Center at Orlando; Department of Veteran Affairs, NY Harbor Campus

INTRODUCTION: According to the National Comprehensive Cancer Network (NCCN) Guidelines, alternatives to definitive treatment include active surveillance for men with low-risk (LR) prostate cancer and a life expectancy ≥ 10 years, as well as androgen deprivation alone for men with high-risk (HR) disease who are not candidates for definitive therapy. In this study, we utilized the Surveillance, Epidemiology, and End Results (SEER) Database to analyze the trends for selection of definitive treatment in a young patient population (age < 60 years).

MATERIALS AND METHODS: We identified all men < 60 years old who were diagnosed with nonmetastatic prostate adenocarcinoma from 2010–2011 and had a follow-up time > 6 months. Detailed clinical and pathologic factors were collected, including the T-stage, Gleason scores, and prostate-specific antigen, and these data were used to group men into NCCN risk groupings. Receipt of treatment was categorized as no definitive treatment, local treatment (such as cryotherapy or transurethral resection of the prostate [TURP]), radical prostatectomy (RP), and radiation therapy (RT). Since androgen deprivation is not recorded in the SEER database, these men were included as having no definitive treatment. Descriptive analyses were used to determine rates of treatment receipt. Multivariate logistic regression was used to determine predictors for selecting treatment other than definitive therapy.

RESULTS: There were a total of 16,630 men identified. Of these subjects, 7,281 (43.8%) had LR disease, 5,660 (34%) had intermediate-risk (IR) disease, and 3,689 (22.2%) had HR disease. The median age at diagnosis was 55 years (interquartile range [IQR]: 52–58 yr). For those with LR disease, 20.5% pursued no definitive treatment, 0.3% pursued local treatment, 57.8% pursued RP, and 21.3% underwent RT. For IR disease, 8.0% pursued no definitive treatment, 0.7% underwent local treatment, 69.2% underwent RP, and 22.0% received RT. For HR disease, 25.5% underwent no definitive treatment, 1.3% underwent local treatment, 51.5% received RP, and 21.8% received RT. On multivariate logistic regression, African-American race (odds ratio [OR] = 0.76; 95% confidence interval [CI], 0.68–0.85; P < .001), and the presence of HR disease (OR = 0.74; 95% CI, 0.67–0.81; P < .001) were associated with a decreased likelihood of selecting definitive treatment.

CONCLUSION: In this young patient population, no definitive treatment was selected in 22.5% of men with LR disease. For those with HR disease, 25.5% did not undergo active treatment, indicating that these men appear to be receiving less aggressive therapy than recommended by NCCN guidelines. In addition, African-American race is also associated with a decreased likelihood for receipt of definitive therapy.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
Related Content